The More You Know: How a multidisciplinary career lends a valuable perspective to Syantra’s research team

Feb 08, 2023

The typical career journey for a scientist is fairly linear. Whether it’s chemistry, biology, physics or another, once a scientist commits to a field, it’s not unusual to stay on that track from university to retirement.


But a lens focused on only one speciality can make it challenging to leverage the many ways these disciplines can crossover. Imagine the possibilities of a single scientist who brings expertise from more than three disciplines to research. Sounds too good to be true, right?


Not for Syantra, a precision healthcare company in Calgary, Alberta. They recently added Olesya Kharenko, PhD to their research team, so they know exactly what it’s like to have this integrated, multi-disciplinary expertise on deck.


Olesya’s 15+ year career has had many interesting twists and turns; the result of an almost insatiable hunger for learning. She’s completed a bachelor’s, masters and PhD degree, published research and conducted studies in bio-organic chemistry, epigenetics, oncology and drug discovery. Today, Olesya is bringing that multi-disciplinary perspective to her work at Syantra. 


But Olesya’s journey has not been circumstantial. Each evolution was a step toward something bigger — something that has the potential to save lives. And after her own mother was diagnosed with breast cancer years ago, Olesya found fulfillment performing cancer research at Syantra as Senior Scientist, Molecular Discovery.

“For me [Syantra] is very exciting because it’s a space where I can have the maximum impact. I can apply my knowledge and expertise in breast cancer, general oncology and drug discovery to hopefully save lives. That's very fulfilling and motivating.”

How do you think your unique career path benefits cancer research?

In retrospect, it would’ve been easier to stay in one field [laughs]. I already had a name established in bio-organic chemistry. But it was my intention to challenge myself, to learn whatever it took to become a biologist, to gain experience in drug discovery and to eventually become an expert in oncology.


Coming from a chemistry background helps me to combine the mindset of the chemist and biologist and to integrate both expertises into the drug discovery and ongoing research.


For example, when I'm looking at research and mechanisms in oncology, I always come across novel drugs, how they work, their chemical structure, I understand it all. It makes sense. So, it’s had its challenges, but it’s been super helpful.

What made you choose breast cancer?

In 2008, my mom was diagnosed with breast cancer, and that motivated me to lean into my work and become an expert in breast cancer.


I think cancer is much scarier when you don’t know much about it. So I dove deeper and deeper into the research, how the therapies work, how cancers are introduced to chemotherapy, and so on.


Luckily, my mom went through treatment and she's now a breast cancer survivor. For me, my mom’s cancer was a huge motivating factor to learn as much as I could. Because the more I learned about it, the more it gave me hope.

What are you most looking forward to in Syantra's future?

Right now, Syantra is really known for the Syantra DX™ Breast Cancer blood test. But we have several other very cool projects going on behind the scenes.


Syantra has a platform which is quite versatile and has the potential to not just to be a piece of detection, but could be transferable to multiple cancer indications. And eventually it could be a tool in monitoring progression and things like that. Digging deeper into all of these interesting mechanisms, oncogenic signals and signatures has all been part of my work. It’s a multi project initiative and it's definitely going to grow even more because there is so much potential.


For me it's very exciting because it’s a space where I can have the maximum impact. I can apply my knowledge and expertise in breast cancer, general oncology and drug discovery to hopefully save lives. That's very fulfilling and motivating.

What do you like to do in your spare time?

Before I moved to Calgary I was mesmerized by its proximity to the mountains. I’m completely in love with the Canadian Rockies, so almost every weekend I’m out hiking or skiing. I can honestly say, having lived in different countries, it’s the best city in the world to me because it offers so much. Having this vast natural landscape in our backyard…you just can't find that anywhere else…

Syantra press release graphic dated November 14, 2023
14 Nov, 2023
Syantra announces additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease.
01 Nov, 2023
CALGARY, AB. - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DX™ Breast Cancer , announced that Rob Lozuk has been appointed as Chief Executive Officer, effective November 1, 2023. “Rob brings over 23 years of experience successfully scaling and transacting commercially disruptive technologies across the healthcare landscape,” said Kristina Rinker, PhD, Chief Scientific Officer and Co-founder of Syantra. “We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection. Rob will bring substantial value to our organization as we expand into the United States with commercial introduction of the Syantra DX™ Breast Cancer test, a blood test that identifies individuals who may have breast cancer, including early-stage disease.” “The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable. Entirely too many early-stage cancers are still being missed, at a time when the opportunity for intervention and survival is the greatest. Truly disruptive healthcare technologies are generational – and that’s exactly what Syantra’s liquid biopsy platform will become” states CEO of Syantra, Rob Lozuk, and adds, “I’m thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena. Our AI-powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body’s immune response that allows cancer to develop. We will rapidly expand the clinical data of the Syantra DX™ Breast Cancer blood test over the remainder of 2023 in preparation for broad global commercialization in 2024.” Within the precision biotech space, Syantra’s liquid biopsy platform has already demonstrated impressive performance statistics as exemplified in the Analytical and Clinical Performance from the Early Analysis of the International Identify Breast Cancer (IDBC) Study, presented by Professor Nigel Bundred, Surgical Oncologist with the Manchester University NHS Foundation Trust, Wythenshawe Hospital, at the 13th European Breast Cancer Conference in Barcelona, Spain, in November of 2022. About Rob Lozuk Prior to joining Syantra, Rob was the Chief Business Officer at Cardea Bio, which culminated in a sale to Paragraf in 2023. Rob was also the President of Specific Diagnostics, which was sold to bioMérieux in 2022. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, a pioneer in revolutionizing the prenatal space, which was successfully transacted to Lab Corp (LH). Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific’s Advanced Staining Business and served as Director of Sales, Marketing and Business Development. About Syantra, Inc. Syantra is a precision biotechnology company changing the way cancer is detected and treated with revolutionary high-performance blood-based tests providing a new way to help detect cancer. Syantra’s scalable, patent-protected platform is based on changes in the immune system and other systemic factors that occur when a cancer tumor is present. These changes can be measured through mRNA biomarkers that are contained in a small amount (2.5ml) of blood. When biomarker expression is combined with patient characteristics, there is a high correlation to the presence or absence of disease. The Syantra platform includes a custom real-time PCR process with proprietary software that includes machine learning-based algorithms. Syantra’s blood testing platform provides a cost-effective way to help identify individuals who may have cancer and should be further evaluated. About the Syantra DX™ Breast Cancer test Syantra is changing the way cancer is detected and treated. Its flagship product, Syantra DX™ Breast Cancer , is a minimally invasive and high-performance blood test for the detection of breast cancer signals at the earliest stages, when breast cancer is easier to treat. The Syantra DX™ Breast Cancer test will be available to women in Canada and the United States in early 2024.
Cara Campbell, breast cancer survivor, poses for a photo with her grandson, Rhett.
22 Aug, 2023
At age 29, Cara woke up with a small lump on her chest. Cara made sure to visit her doctor right away for a thorough breast exam and mammogram. Two weeks later, after an ultrasound and a biopsy, Cara was diagnosed with breast cancer.
Katie Smith-Parent, stage two hormone-positive breast cancer survivor,  smiles in her kitchen.
25 May, 2023
In her early 30s, Katie Smith-Parent noticed a lump on her breast. She was initially told by a doctor not to worry and that the lump would go away on its own. She trusted her instincts and after finding a new doctor, she was diagnosed with stage two hormone-positive breast cancer. Today, she is an advocate for early detection and oncofertility.
Syantra Press Release graphic dated April 18, 2023
18 Apr, 2023
Syantra announced today that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Syantra press release dated January 18, 2023 announcing promotion of Carol Roesler to VP
16 Jan, 2023
Syantra Inc. announced today the promotion of Carol Roesler to Vice President, effective January 2023. Carol will maintain her current responsibilities in her new role, in addition to supporting Canadian business development for the Syantra DX™ Breast Cancer test.
Syantra DX Breast Cancer requisition with blood test tube
08 Nov, 2022
Syantra will present findings from the IDBC Study at the 13th European Breast Cancer Conference, held in Barcelona, Spain from 16 -18 November 2022.
Syantra press release dated October 27, 2022 announcing appointment of Dr. Massimo Cristofanilli
27 Oct, 2022
Syantra appoints Dr. Massimo Cristofanilli, a world-renowned leader in the field of breast cancer, to its Scientific Advisory Board (SAB) effective Sept 1, 2022. Dr. Cristofanilli is a Professor of Medicine, Chief of Breast Medical Oncology and Associate Director of Precision Medicine at Weill-Cornell Medicine.
Jesslyn Davies, a 33-year-old woman battling breast cancer, smiling in her Calgary home
18 Oct, 2022
In November 2020, Jesslyn Davies, a 33-year-old registered nurse and mother of two young boys, noticed a small cyst on her breast. Soon after, she was diagnosed with Triple Negative Stage 2B breast cancer.
Matalyn Schall poses with Syantra team wearing white lab coats at Syantra lab.
06 Oct, 2022
Since winning Miss Junior Teen Calgary pageant in April 2022, Matalyn Schall has been raising awareness of the importance of early breast cancer detection. That's when she found Syantra, a precision health care company that can detect breast cancer in the blood even at the earliest stages.
More Posts
Share by: